Replies to post #209013 on Biotech Values

[ghmm]

SRPT:

That sounds extremely optimistic to me.

Since we'll probably agree on prevalence I am curious what part(s) you think are optimistic (Avg cost per patient, % reimbursed, how long it will take to reach 2/3 penetration)?